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Background: For patients with initially unresectable liver metastases from colorectal cancer, chemotherapy can down-
size metastases and facilitate secondary resection. We assessed the efﬁcacy of bevacizumab plus modiﬁed FOLFOX-6
(5-ﬂuorouracil/folinic acid, oxaliplatin) or FOLFOXIRI (5-ﬂuorouracil/folinic acid, oxaliplatin, irinotecan) in this setting.
Patients and methods: OLIVIAwas a multinational open-label phase II study conducted at 16 centres in Austria, France,
Spain, and the UK. Patients with unresectable liver metastases were randomised to bevacizumab (5 mg/kg) plus mFOLFOX-
6 [oxaliplatin 85 mg/m2, folinic acid 400 mg/m2, 5-ﬂuorouracil 400 mg/m2 (bolus) then 2400 mg/m2 (46-h infusion)] or
FOLFOXIRI [oxaliplatin 85 mg/m2, irinotecan 165 mg/m2, folinic acid 200 mg/m2, 5-ﬂuorouracil 3200 mg/m2 (46-h infusion)]
every 2 weeks. Unresectability was deﬁned as ≥1 of the following criteria: no possibility of upfront R0/R1 resection of all
lesions; <30% residual liver volume after resection; metastases in contact with major vessels of the remnant liver.
Resectability was evaluated by multidisciplinary review. The primary end point was overall resection rate (R0/R1/R2). Efﬁcacy
end points were analysed by intention-to-treat analysis.
Results: In patients assigned to bevacizumab–FOLFOXIRI (n = 41) or bevacizumab–mFOLFOX-6 (n = 39), the overall resec-
tion rate was 61% [95% conﬁdence interval (CI) 45% to 76%] and 49% (95% CI 32% to 65%), respectively (difference 12%;
95% CI −11% to 36%). R0 resection rates were 49% and 23%, respectively. Overall tumour response rates were 81% (95%
CI 65% to 91%) with bevacizumab–FOLFOXIRI and 62% (95% CI 45% to 77%) with bevacizumab–mFOLFOX-6. Median
progression-free survival (PFS) was 18·6 (95% CI 12.9–22.3) months and 11·5 (95% CI 9.6–13.6) months, respectively. The
most common grade 3–5 adverse events were neutropenia (bevacizumab–FOLFOXIRI, 50%; bevacizumab–mFOLFOX-6,
35%) and diarrhoea (30% and 14%, respectively).
Conclusions: Bevacizumab–FOLFOXIRI was associated with higher response and resection rates and prolonged PFS
versus bevacizumab–mFOLFOX-6 in patients with initially unresectable liver metastases from colorectal cancer. Toxicity was
increased but manageable with bevacizumab–FOLFOXIRI.
ClinicalTrials.gov: NCT00778102.
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introduction
The liver is the most common site of metastasis in patients with
colorectal cancer. Treatment strategies that allow hepatic
resection as part of an interdisciplinary consensus offer better 5-
year survival rates than palliative treatment alone [1, 2]. Patients
with liver-only metastases [colorectal liver metastases (CLM)]
seem to be an exceptional group with regard to the possible ben-
eﬁts of potentially curative multidisciplinary strategies [3].
Clariﬁcation of resectability status, i.e. upfront or potentially
resectable as opposed to clearly unresectable disease, before any
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treatment decision is of utmost importance. Categorisation of
CLM has been previously described, and we know that for
selected patients with borderline resectable CLM, chemotherapy
can downsize metastases and facilitate secondary resection [4, 5].
Currently, there is no standard of care for patients with bor-
derline resectable CLM, and treatment guidelines permit several
combinations [6–8]. Conducting trials in this area is hampered
by the lack of a standard regimen and variable deﬁnitions for
unresectability [4, 6]. Despite clear eligibility criteria [9, 10], the
patient population that is recruited is often variable with respect
to anatomical and potentially biological demographics.
Standard chemotherapy regimens, i.e. infused 5-ﬂuorouracil/
folinic acid plus irinotecan (FOLFIRI) or oxaliplatin (FOLFOX),
facilitate secondary resection and are accepted treatment
options in patients with initially unresectable CLM [5]. NCCN
and ESMO guidelines [6, 7] suggest treatment with the most
active combination regimen upfront, which often comprises
doublet chemotherapy plus a targeted agent (e.g. bevacizumab
or cetuximab for KRAS wild-type tumours), although few
studies of these regimens have been done speciﬁcally in patients
with initially unresectable CLM.
This randomised multicentre phase II study evaluated resec-
tion rates and safety of bevacizumab plus modiﬁed FOLFOX-6
(mFOLFOX-6) or bevacizumab plus FOLFOXIRI in patients
with initially clearly deﬁned unresectable CLM. ‘Unresectability’
was determined by a multidisciplinary team to permit a prag-
matically deﬁned patient population.
patients andmethods
study design
OLIVIA was a multicentre, open-label, randomised phase II study. The
primary end point was the overall resection rate (R0/R1/R2). Secondary end
points included overall response rate, time to response, histopathological re-
sponse, progression-free survival (PFS), relapse-free survival (RFS), overall
survival, and surgical safety. The study was carried out in accordance with
the Declaration of Helsinki and all patients provided written informed
consent before enrolment. The protocol was approved by institutional or re-
gional ethics committees.
patients
Patients with previously untreated, upfront unresectable, histologically con-
ﬁrmed colorectal cancer with metastases conﬁned to the liver were eligible.
Patients had to meet ≥1 of the following criteria for unresectability of hepatic
metastases as assessed by a local multidisciplinary team: no upfront R0/R1 re-
section of all hepatic lesions possible; <30% estimated residual liver volume
after resection; and metastases in contact with major vessels of the remnant
liver. Hepatic lesions were assessed using three-phase computed tomography
(CT) or magnetic resonance imaging (MRI) including liver-speciﬁc contrast.
Fluorodeoxyglucose–positron emission tomography (FDG–PET) was carried
out to exclude extrahepatic metastases. The patient’s general condition had to
be such that major abdominal surgery was feasible.
Other inclusion criteria were: age ≥18 years; Eastern Cooperative Oncology
Group (ECOG) performance status ≤1. Exclusion criteria included prior
(neo)adjuvant chemotherapy completed <6 months before randomisation and
any extrahepatic disease.
randomisation and masking
Randomisation (block size 10) was stratiﬁed according to centre (n = 16),
ECOG performance status (0 or 1), and number of baseline metastatic
lesions (<3 or ≥3). No masking was employed for patients or investigators
giving interventions and assessing outcomes.
treatment
preoperative chemotherapy. Patients were randomly assigned (1 : 1) to
receive bevacizumab plus mFOLFOX-6 or bevacizumab plus FOLFOXIRI.
Bevacizumab 5 mg/kg was given by i.v. infusion on day 1 every 2 weeks.
mFOLFOX-6 consisted of oxaliplatin 85 mg/m2, folinic acid 400 mg/m2, and
bolus 5-ﬂuorouracil 400 mg/m2 followed by 2400 mg/m2 as a 46-h continuous
infusion on day 1 every 2 weeks. FOLFOXIRI consisted of oxaliplatin
85 mg/m2, irinotecan 165 mg/m2, folinic acid 200 mg/m2, and 5-ﬂuorouracil
3200 mg/m2 as a 46-h continuous infusion on day 1 every 2 weeks. The
chemotherapy cycle before resection was given without bevacizumab.
post-operative chemotherapy. Patients rendered tumour free (R0/R1
resection) resumed study treatment of eight additional cycles starting 4–6
weeks after surgery (following conﬁrmation of complete resection by CT 4
weeks after surgery and after complete wound healing). Patients with
residual disease after surgery (R2 resection) and unresected patients
continued study treatment until disease progression, unacceptable toxicity,
or patient refusal. After 12 cycles of study treatment, oxaliplatin could be
discontinued in the bevacizumab–mFOLFOX-6 arm, and ≥1 cytotoxic agent
had to be discontinued in the bevacizumab–FOLFOXIRI arm.
tumour assessments and surgery
Tumour status was assessed every 6 weeks and preoperatively (within 4
weeks of surgery) using CT or MRI. The technique used (CT or MRI) was
left to the discretion of the assessor. Surgery was carried out without further
cycles as soon as the appropriate tumour reduction for potential curative re-
section was evident. Resectability was evaluated by a multidisciplinary
review team, including at least a liver surgeon, radiologist, and medical on-
cologist. Patients deemed resectable were offered surgery 5–7 weeks after
their last bevacizumab dose and 3–5 weeks after their last chemotherapy
cycle. As per the protocol, radiofrequency ablation was allowed only for
lesions with an unfavourable location (noted in the electronic case report
form accordingly as a suboptimal surgical approach). A two-stage approach
to achieve tumour clearance was permitted.
Resection status (R0/R1/R2) was evaluated by histopathological assess-
ment of excised metastases together with the operation notes. Follow-up
tumour assessments were carried out 4 weeks after surgery; clinical assess-
ments of surgical outcomes and safety were carried out at the time of surgery,
and 48 h, 1 and 3 months post-surgery. Follow-up assessments were carried
out at the end of postoperative therapy, every 3 or 6 months (in patients with
progressive disease) for the ﬁrst 12 months, and annually thereafter.
End points are deﬁned in the supplementary Material, available at Annals
of Oncology online.
statistical analysis
The sample size (40 patients/treatment group) was based on feasibility and
allowed a reasonably precise estimate of resection rates in each treatment
arm. The study was not powered for conﬁrmatory hypothesis testing of treat-
ment comparisons; therefore, all statistical analyses were exploratory only.
The ﬁnal study analysis, the cut-off date for which was 22 November
2013, is presented. Efﬁcacy end points were analysed according to the inten-
tion-to-treat (ITT) principle. Overall resection rate was presented by treat-
ment arm with exact two-sided 95% Pearson–Clopper conﬁdence intervals
(CIs). Time-to-event end points were analysed using Kaplan–Meier
methods; estimates for median values were presented with 95% CIs.
This trial is registered with ClinicalTrials.gov, number NCT00778102.
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results
patients
From October 2008 to December 2011, 80 patients were enrolled
at 16 sites in Austria, France, Spain, and the UK and were
included in the ITT population (bevacizumab–FOLFOXIRI,
n = 41; bevacizumab–mFOLFOX-6; n = 39) (supplementary
Figure S1, available at Annals of Oncology online). Treatment
groups were generally well balanced, although patients in the bev-
acizumab–FOLFOXIRI group were slightly older, and included
more men at baseline than the bevacizumab–mFOLFOX-6 group
(Table 1). Although ECOG performance status was a stratiﬁcation
factor, an imbalance developed between arms in the 28 days
between randomisation and ﬁrst drug intake resulting in an un-
favourable distribution for the bevacizumab–FOLFOXIRI arm.
Seventy-seven patients (bevacizumab–FOLFOXIRI, n = 40;
bevacizumab–mFOLFOX-6, n = 37) received treatment and
were included in the safety population. Treatment exposure is
described in the supplementary Material and Table S1, available
at Annals of Oncology online.
surgery
Median time to resection in the ITT population was similar in
both treatment groups (bevacizumab–FOLFOXIRI, 4.3 months;
bevacizumab–mFOLFOX-6, 4.4 months). Surgery (segmentectomy,
Table 1. Baseline characteristics (intention-to-treat population)
Variable Bevacizumab plus FOLFOXIRI
(N = 41)
Bevacizumab plus
mFOLFOX-6 (N = 39)
n % n %
Sex
Male 29 71 18 46




ECOG performance status at baseline
0 23 56 31 80
1 16 39 8 21
2a 2 5 0 0
Criteria for unresectabilityb
No upfront R0/R1 resection of hepatic lesions possible 33 80 31 80
Less than 30% estimated residual liver after resection 26 63 23 59
Disease in contact with major vessels of remnant liver 15 37 17 44
Primary tumour site
Colon 29 71 27 69
Rectum 8 20 9 23
Colorectal 4 10 3 8
Tumour differentiation
Well differentiated 8 20 8 21
Moderately differentiated 21 51 24 62
Poorly differentiated 3 7 2 5
Undetermined/unknown 9 22 5 13
No. of metastatic lesions at baseline
<3 2 5 3 8
≥3 39 95 36 92
Disease stage at diagnosis
Locoregional 11 27 7 18
Metastatic 30 73 32 82
Primary tumour in situ
Yes 25 61 27 69
No 16 39 12 31
Percentages may not add up to 100% due to rounding or patients meeting ≥1 unresectability criterion.
aTwo patients had an ECOG score of 1 at randomisation, but had an ECOG score of 2 before study drug administration (baseline).
bBased on manual medical science review of the case report forms.
ECOG, Eastern Cooperative Oncology Group; FOLFOXIRI, infused 5-fluorouracil, folinic acid, oxaliplatin, and irinotecan; mFOLFOX-6, modified
infused 5-fluorouracil, folinic acid, and oxaliplatin.
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sectorectomy or hemihepatectomy) was carried out in 44 patients
(bevacizumab–FOLFOXIRI, n = 25; bevacizumab–mFOLFOX-6;
n = 19). Nine of 52 patients (bevacizumab–FOLFOXIRI, n = 5;
bevacizumab–mFOLFOX-6; n = 4), with primary tumours in situ
had primary resection surgery during the study. Eleven patients
had preoperative portal vein embolisation (bevacizumab–
FOLFOXIRI, n = 5; bevacizumab–mFOLFOX-6; n = 6). Ten
patients had adjunctive radiofrequency ablation (bevacizumab–
FOLFOXIRI, n = 5; bevacizumab–mFOLFOX-6; n = 5). Median
duration of hospitalisation after ﬁrst surgery was 11 (range, 5–
39) days in the bevacizumab–FOLFOXIRI group and 9 (range,
5–39) days in the bevacizumab–mFOLFOX-6 group.
efﬁcacy
The overall resection rate for ﬁrst resections—the primary end
point—was 61% (95% CI 45% to 76%) in the bevacizumab–
FOLFOXIRI group and 49% (95% CI 32% to 65%) in the bevaci-
zumab–mFOLFOX-6 group (difference 12%; 95% CI –11% to
+36%; Table 2). The R0 resection rate was numerically higher
Table 2. Efficacy outcomesa
Variable Bevacizumab plus
FOLFOXIRI (N = 41)
Bevacizumab plus
mFOLFOX-6 (N = 39)
Difference or hazard
ratio (95% CI)
Resection rate (first resection)
Overall (R0/R1/R2), n (%) 25 (61) 19 (49) 12 (−11 to 36)
95% CI 45–76 32–65
R0/R1, n (%) 21 (51) 13 (33) 18 (−5 to 41)
95% CI 35–67 19–50
R0, n (%) 20 (49) 9 (23) 26 (4 to 48)
95% CI 33–65 11–39
R1, n (%) 1 (2) 4 (10)
R2, n (%)b 4 (10) 6 (15)
Not resected, n (%) 16 (39) 20 (51)
Histopathological responsec
Patients in analysis, n 21 14
Histopathological response rate, n (%)d 11 (52) 8 (57) −5 (−43 to 34)
95% CI 30–74 29–82
Complete response, n (%) 1 (5) 0
Major response, n (%) 10 (48) 8 (57)
Minor response, n (%) 7 (33) 4 (29)
Unknown, n (%) 3 (14) 2 (14)
Overall response rate (confirmed), n (%)e 33 (81) 24 (62)
95% CI 65–91 45–77 19 (−2 to 40)
Complete response, n (%)f 22 (54) 9 (23)
Partial response, n (%) 11 (27) 15 (39)
Stable disease, n (%) 5 (12) 13 (33)
Progressive disease, n (%) 0 1 (3)
Unknown, n (%) 3 (7) 1 (3)
Time to response
Median (95% CI), months 3.1 (1.9–3.9) 3.1 (2.7–8.6)
Relapse-free survivalg
Patients in analysis, n 21 13
Median (95% CI), months 17.1 (12.3–NR) 8.1 (3.8–11.7) 0.31 (0.12–0.75)
Progression-free survival
Median (95% CI), months 18.6 (12.9–22.3) 11.5 (9.6–13.6) 0.43 (0.26–0.72)
aIntention-to-treat population unless otherwise stated.
bTwo patients in each treatment group went on to have a second surgery with an R0 outcome in all cases.
cComplete response, 0% viable tumour cells within resected specimen; major response, 1%–49% viable tumour cells; minor response, 50%–99% viable
tumour cells. Histopathological assessment was carried out after first resection but was not mandatory.
dComplete plus major response.
eAccording to Response Evaluation Criteria In Solid Tumours (RECIST), version 1. In patients who underwent liver resection, radiological
confirmation of complete response was performed after surgery and thus would include treatment effects from both chemotherapy and surgery.
fOf the patients with a complete response, one patient in each treatment group had >5 target lesions and all remaining patients had 1–5 target lesions.
gAssessed in patients with a R0/R1 outcome after first resection.
CI, confidence interval; FOLFOXIRI, infused 5-fluorouracil, folinic acid, oxaliplatin, and irinotecan; mFOLFOX-6, modified infused 5-fluorouracil,
folinic acid, and oxaliplatin; NR, not reached.
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with bevacizumab–FOLFOXIRI (49%; 95% CI 33% to 65%)
compared with bevacizumab–mFOLFOX-6 (23%; 95% CI 11%
to 39%). Two patients in each group with residual disease fol-
lowing initial surgery (R2 resections) had pre-planned two-stage
hepatectomies; all four patients had an R0 outcome after the
second surgery. The ﬁnal R0 resection rates were 54% (95% CI
37% to 69%) with bevacizumab–FOLFOXIRI and 31% (95% CI
17% to 48%) with bevacizumab–mFOLFOX-6.
Overall tumour response rate was 81% (95% CI 65% to 91%)
with bevacizumab–FOLFOXIRI and 62% (95% CI 45% to 77%)
with bevacizumab–mFOLFOX-6. Median time to response
was similar in both treatment groups (3.1 months). The histo-
pathological response rate (complete/major) was 52% with bev-
acizumab–FOLFOXIRI (11 of 21 patients) and 57% with
bevacizumab–mFOLFOX-6 (8 of 14 patients).
Median PFS in the ITT population was numerically longer
with bevacizumab–FOLFOXIRI (18.6 months; 95% CI 12.9–
22.3 months) than with bevacizumab–mFOLFOX-6 (11.5
months; 95% CI 9.6–13.6 months) (hazard ratio 0.43; 95% CI
0.26–0.72; supplementary Figure S2, available at Annals of
Oncology online). PFS according to outcome of ﬁrst surgery is
presented in supplementary Figure S2, available at Annals of
Oncology online.
Median RFS, which was assessed in patients with an R0/R1
status after ﬁrst resection, was 17.1 months (95% CI 12.3
months to not reached) with bevacizumab–FOLFOXIRI
(n = 21) and 8.1 (95% CI 3.8–11.7) months with bevacizumab–
mFOLFOX-6 (n = 13) (hazard ratio 0.31; 95% CI 0.12–0.75).
Eight patients in the bevacizumab–FOLFOXIRI group and 19
in the bevacizumab–mFOLFOX-6 group died. Median time to
overall survival was not reached (range 0–56.0 months) in the
bevacizumab–FOLFOXIRI group and was 32·2 (range 0.7–59.6)
months in the bevacizumab–mFOLFOX-6 group (hazard ratio
0.35; 95% CI 0.15–0.80).
safety
Toxicity events (all grades) occurred in 100% of patients in both
groups, and a grade ≥3 event occurred in 38 bevacizumab–
FOLFOXIRI patients (95%) and 31 bevacizumab–mFOLFOX-6
patients (84%; supplementary Table S2, available at Annals of
Oncology online). The most frequently occurring grade ≥3
adverse events were neutropenia (bevacizumab–FOLFOXIRI,
50%; bevacizumab–mFOLFOX-6, 35%), diarrhoea (bevacizu-
mab–FOLFOXIRI, 30%; bevacizumab–mFOLFOX-6, 14%), and
febrile neutropenia (bevacizumab–FOLFOXIRI, 13%; bevacizu-
mab–mFOLFOX-6, 8%). Grade ≥3 peripheral neuropathy was
rare (bevacizumab–FOLFOXIRI, n = 1). With the exception of
grade 3–5 venous thromboembolic events and diarrhoea, all
other grade 3–5 bevacizumab-associated events occurred infre-
quently (<8%).
Adverse events causing discontinuation of bevacizumab oc-
curred in 8 patients (20%) in the bevacizumab–FOLFOXIRI
group and 13 patients (35%) in the bevacizumab–mFOLFOX-6
group. One patient in the bevacizumab–FOLFOXIRI group died
of disseminated intravascular coagulation related to sepsis that oc-
curred after emergency surgery due to perforation during an intes-
tinal stenting procedure. This was considered by the investigator
to be causally related to pre-existing disease. Two patients in the
bevacizumab–mFOLFOX-6 group died of hepatic failure. One of
these patients received 13 cycles of bevacizumab–mFOLFOX-6
and died 37 days after surgery (64 days after chemotherapy) after
developing hepatic and renal failure. The other patient received 12
cycles of bevacizumab–mFOLFOX-6 and died 20 days after
surgery (136 days after chemotherapy) after developing multiple
organ failure. Both events were judged to be related to surgery
after extended systemic treatment.
In the surgical safety population (bevacizumab–FOLFOXIRI,
n = 25; bevacizumab–mFOLFOX-6; n = 19), all-grade surgery-
related events were reported in 15 patients (60%) in the
bevacizumab–FOLFOXIRI group and 15 (79%) in the bevacizu-
mab–mFOLFOX-6 group; grade 5 events were reported in 0 (0%)
and 2 (11%) patients, respectively (supplementary Table S3, avail-
able at Annals of Oncology online). No anastomotic leaks were
observed after resection of the primary tumour.
discussion
There are currently limited data to deﬁne the optimal treatment
approach for patients with unresectable liver-only metastases, es-
pecially as resectability is determined—through necessity—by a
multidisciplinary team on a patient-by-patient basis. Accepting
these limitations, results from the OLIVIA study suggest that
bevacizumab plus FOLFOXIRI improves tumour response rates,
resection rates, and PFS in patients with upfront deﬁned unre-
sectable CLM compared with bevacizumab plus mFOLFOX-6.
Although the ﬁndings can be viewed as exploratory only, the
trends in favour of the bevacizumab–FOLFOXIRI combination
are consistent for all end points. Although toxicity was clearly
greater in the four-agent arm, no new safety concerns were iden-
tiﬁed. Our ﬁndings support the feasibility of the addition of iri-
notecan to FOLFOX in combination with bevacizumab, which
offers an effective treatment option in patients with initially unre-
sectable CLM and may allow them to progress to surgery. They
also compliment phase II and III studies which support the efﬁ-
cacy of bevacizumab–FOLFOXIRI in patients with unresectable
metastatic disease [11, 12].
Although combination regimens have been tested in patients
with initially unresectable liver-limited disease in a few studies,
data in this patient group remain limited (supplementary
Table S4, available at Annals of Oncology online) [9, 10, 13–15].
Ye et al. [15] showed that cetuximab plus chemotherapy
(mFOLFOX6 or FOLFIRI) improved both resectability and
overall survival compared with chemotherapy alone supporting
the use of this regimen in patients with KRAS wild-type CLM.
The OLIVIA study provides an estimate of the efﬁcacy of bevaci-
zumab-containing regimens in patients with initially unresectable
liver-limited disease. While OLIVIA did not include a chemo-
therapy-only arm, the activity demonstrated by bevacizumab–
FOLFOXIRI compares favourably with other regimens tested in
this patient group (supplementary Table S4, available at Annals of
Oncology online). We suggest further testing of bevacizumab–
FOLFOXIRI in clinical trials of patients with initially unresectable
CLM.
Our results concur with the ﬁndings from two phase III trials
in patients with inoperable disease, which also showed that the
addition of a third chemotherapeutic agent to a chemotherapy
doublet (with or without a targeted agent) offered improved
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efﬁcacy [11, 16]. The response rate achieved with bevacizumab–
FOLFOXIRI in OLIVIA (81%) is higher than that reported in
TRIBE with the same regimen (65%) [11], supporting the hy-
pothesis that patients with liver-limited disease respond better.
In the absence of a standardised deﬁnition for resectability, a
key issue for any study involving patients with unresectable or
borderline resectable CLM is how to identify the target popula-
tion. To date, four other studies have been carried out in this
patient group, all of whom were deemed unresectable by a
multidisciplinary team (supplementary Table S4, available at
Annals of Oncology online) [9, 10, 13, 15]. The OLIVIA study
included three a priori criteria for unresectability speciﬁed by a
multidisciplinary team. FDG–PET scanning was also manda-
tory at baseline to exclude patients with extrahepatic disease. We
suggest that OLIVIA included a homogeneous patient popula-
tion with initially unresectable CLM, and recommend our deﬁn-
ition of unresectabilty for further evaluation, especially if
technical unresectabilty deﬁnes the target population.
No new or unexpected safety signals were observed in the
OLIVIA trial. The incidence of grade ≥3 neutropenia in both
the bevacizumab–FOLFOXIRI and bevacizumab–mFOLFOX-6
groups was consistent with other recent phase II/III trials of these
regimens [11, 12, 17, 18], although the rate of febrile neutropenia
with bevacizumab–FOLFOXIRI was slightly higher than expected
[11, 12]. Grade ≥3 diarrhoea was also slightly more common
than previously documented with both regimens [11, 12, 17, 18].
These data are consistent with the expected but manageable toxi-
cities associated with four-agent systemic therapy. One patient in
the bevacizumab–FOLFOXIRI group died of disseminated intra-
vascular coagulation during conversion therapy, and two patients
in the bevacizumab–mFOLFOX-6 group died of hepatic failure
during the post-operative period after ≥12 courses of preoperative
treatment. This outcome concurs with Cauchy et al. [19] who
reported an increased rate of mortality and major morbidities in
patients with initially unresectable CLM who received ≥12 cycles
of preoperative chemotherapy.
Bleeding and wound-healing complications are potential
adverse events of bevacizumab that can interfere with peri-op-
erative continuation of therapy. However, liver surgery can be
carried out safely without a marked increase in post-operative
complications if bevacizumab is discontinued 4–5 weeks before
surgery [20, 21]. The incidences of grade ≥3 bleeding, wound-
healing complications, and gastrointestinal perforation in our
study are in line with the large observational First BEAT study
[22] and a comparative study [23].
In OLIVIA, treatment was continued after surgery as recom-
mended by current treatment guidelines [6–8], even though
supporting data are limited. Of interest are the ﬁndings from the
HEPATICA trial, which compared bevacizumab plus capecita-
bine and oxaliplatin (CAPOX) with CAPOX alone given after
radical resection of CLM [24]. Even though the study was closed
before completion, a higher 2-year disease-free survival rate of
70% was reported with bevacizumab–CAPOX compared with
CAPOX (52%; P = 0.074), providing support for this approach.
The OLIVIA trial was conducted in specialised centres that
allowed a precise assessment of surgery and peri-operative safety
parameters. Study limitations included the exploratory nature of
the ﬁndings, limited sample size, and the primary study end point
(resection rate), which is a surrogate for long-term outcomes.
In conclusion, bevacizumab in combination with FOLFOXIRI
was associated with higher response and resection rates and pro-
longed PFS compared with bevacizumab–mFOLFOX6 in patients
with initially unresectable metastases from colorectal cancer con-
ﬁned to the liver. Bevacizumab plus FOLFOXIRI should be evalu-
ated further in this setting.
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